<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265744</url>
  </required_header>
  <id_info>
    <org_study_id>IM128-027</org_study_id>
    <secondary_id>2014-002184-14</secondary_id>
    <nct_id>NCT02265744</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study evaluating the safety and efficacy of a novel biologic in the treatment of systemic
      lupus erythematosus in male and female adults. Patients who qualify will be randomized to
      either active BMS-931699 or placebo for initially, up to 24 weeks. Patients who complete the
      initial 24 weeks of treatment and who are responding to therapy will have the option to
      continue receiving BMS-931699 as part of a long-term extension (LTE). Disease activity and
      safety will be assessed over the course of the study through laboratory values, various
      rating scales accepted in systemic lupus erythematosus studies and patient self reporting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Subjects completing Day 169 (24 weeks) on study medication may be eligible to enter an
           optional LTE period

        2. The LTE period will remain blinded but will no longer have a placebo arm:

             -  Subjects will remain on their originally assigned treatment arm unless they were on
                placebo

             -  Subjects initially randomized to placebo arm will be automatically re-randomized
                into one of the existing active arms at Day 169 (24 weeks)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2014</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 26, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieve a BICLA Response (BICLA Response Rate) at Day 169</measure>
    <time_frame>At Day 169</time_frame>
    <description>The British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) is a measure of systemic lupus erythematosus (SLE) response. BICLA is defined as: British Isle Lupus Assessment Group improvement, defined as BILAG As at Baseline improved to B/C/D, and BILAG Bs at baseline improved to C/D, and no BILAG worsening in other BILAG organ systems such that there are no new BILAG As or greater than 1 new BILAG B; and no worsening in the SLEDAI-2K total score compared to Baseline (defined as no increase in SLEDAI total score); and no worsening in the physician's global assessment (MDGA) of disease activity (&quot;no worsening&quot; is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Meet Response Criteria for the SLE Responder Index : SRI(4), SRI(5) and SRI(6) at Day 169</measure>
    <time_frame>At Day 169</time_frame>
    <description>SRI is the Systemic Lupus Erythematosus Responder Index. An SRI(4) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 4 points AND (a)no worsening in the physician's global assessment (MDGA) of disease activity (&quot;no worsening&quot; is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline) AND (b) no new BILAG-2004 Index A organ system score AND (c)no more than one new or worsening BILAG-2004 Index B organ system scores.
An SRI(5) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 5 points AND (a) AND (b) AND (c).
An SRI(6) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 6 points AND (a) AND (b) AND (c) The outcomes are better in increasing order from SRI(4) to SRI(5) to SRI(6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Meet Response Criteria for the SLE Responder Index: SRI(4), SRI(5) and SRI(6) at Day 85</measure>
    <time_frame>At Day 85</time_frame>
    <description>SRI is the Systemic Lupus Erythematosus Responder Index. An SRI(4) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 4 points AND (a)no worsening in the physician's global assessment (MDGA) of disease activity (&quot;no worsening&quot; is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline) AND (b) no new BILAG-2004 Index A organ system score AND (c)no more than one new or worsening BILAG-2004 Index B organ system scores.
An SRI(5) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 5 points AND (a) AND (b) AND (c).
An SRI(6) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 6 points AND (a) AND (b) AND (c) The outcomes are better in increasing order from SRI(4) to SRI(5) to SRI(6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With BICLA Response (BICLA Response Rate) at Day 85</measure>
    <time_frame>At Day 85</time_frame>
    <description>BICLA is defined as: British Isle Lupus Assessment Group improvement, defined as BILAG As at Baseline improved to B/C/D, and BILAG Bs at baseline improved to C/D, and no BILAG worsening in other BILAG organ systems such that there are no new BILAG As or greater than 1 new BILAG B; and no worsening in the SLEDAI-2K total score compared to Baseline (defined as no increase in SLEDAI total score); and no worsening in the physician's global assessment (MDGA) of disease activity (&quot;no worsening&quot; is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline; No changes in concomitant medications according to the following criteria: No increase of or addition of a new immunosuppressant agent (azathioprine,mycophenolic acid/mycophenolate mofetil, methotrexate, anti-malarial, leflunomide) over baseline levels; No increase in corticosteroid dose above baseline level outside of those allowed per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CLASI Score at Day 85 and Day 169</measure>
    <time_frame>At Day 85 and Day 169</time_frame>
    <description>Mean change from baseline, CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index. Scores can range from 0 to 70 with higher scores denoting greater disease activity or damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Improvement of &gt;4 or a Decrease of &gt;50% From Baseline in Their Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Score</measure>
    <time_frame>At Day 85 and Day 169</time_frame>
    <description>Mean change from baseline, CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index. Scores can range from 0 to 70 with higher scores denoting greater disease activity or damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Arthritis, as Assessed by American College of Rheumatology (ACR) 28-joint Count of Tender and Swollen Joints on Day 85 and Day 169</measure>
    <time_frame>At baseline, Day 85 and Day 169</time_frame>
    <description>Mean Change from Baseline Over Time; Measured by Disease Activity Score 28: A single score on a continuous scale (0-9.4). The level of RA disease activity can be interpreted as low (DAS28 &lt;=3.2),moderate (3.2 &lt; DAS28 &lt;=5.1), or as high disease activity (DAS28 &gt; 5.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in BILAG-2004 Score of Systemic Lupus Erythematosus (SLE) Activity on Day 85 and Day 169</measure>
    <time_frame>At baseline, Day 85 and Day 169</time_frame>
    <description>Overall British Isles Lupus Assessment Group-2004 score, BILAG Scores: A=Severe disease activity, B=Moderate disease activity, C=Mild disease, D=Inactive disease but previously affected, E=System never involved.The categories are converted to a numeric score (A=9, B=3, C=1, D=0, E=0) and treated as a continuous variable. Higher score= more severe disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Corticosteroid and Immunosuppressant Use</measure>
    <time_frame>Up to one day prior to the first dose of long-term extension period or up to 42 days post last short-term dose date, which ever is earlier</time_frame>
    <description>Percent of participants requiring use of corticosteroids and mmunosuppressants use over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Pre-established Events of Special Interest</measure>
    <time_frame>On or after the first dose date of short-term study medication and up to 42 days post last short-term dose date or up to the day prior to the first dose of long-term extension period, whichever is earlier</time_frame>
    <description>Although there are no identified risks for BMS-931699, BMS has developed a list of events of special interest for the BMS-931699 program based on the known biologic class effects, the mechanism of action of BMS-931699, overall potential consequences of mmunosuppression, and preliminary data from unblinded clinical trials. Event categories of special interest for this study may include, but are not limited to: Infections, Autoimmunity, Malignancies, Injection-related reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Vital Signs:Heart Rate</measure>
    <time_frame>At Day 85 and Day 169</time_frame>
    <description>HEART RATE (HR) Beats per min (BPM): HR &gt; 100 AND CHANGE FROM BASELINE &gt; 30 OR HR &lt; 55 AND CHANGE FROM BASELINE &lt; -15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Vital Signs: Systolic and Diastolic Blood Pressure</measure>
    <time_frame>At Day 85 and Day 169</time_frame>
    <description>SYSTOLIC BLOOD PRESSURE (SYSBP) (MMHG); SYSBP &gt; 140 AND CHANGE FROM BASELINE &gt; 20 OR SYSBP &lt; 90 AND CHANGE FROM BASELINE &lt; -20; DIASTOLIC BLOOD PRESSURE (DIABP) &gt; 90 AND CHANGE FROM BASELINE &gt; 10 OR DIABP &lt; 55 AND CHANGE FROM BASELINE &lt; -10;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Vital Signs: Respiration Rate</measure>
    <time_frame>At Day 85 and Day 169</time_frame>
    <description>RESPIRATION RATE (RESP) (PER MIN) RESP &gt; 16 OR RESP CHANGE FROM BASELINE &gt; 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Vital Signs: Temperature</measure>
    <time_frame>At Day 85 and Day 169</time_frame>
    <description>TEMPERATURE (TEMP) (C) TEMP &gt; 38.3 OR TEMP CHANGE FROM BASELINE &gt; 1.6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Up to 42 days post last dose of short-term double-blind study medication or up to the day prior to the start of long-term extension period, whichever is earlier.</time_frame>
    <description>QTc (corrected QT) Fridericia, PR Interval, QRS Interval and Change from baseline in QTCF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough: Trough Level Serum Concentration of BMS-931699 at Time Point Specified</measure>
    <time_frame>Day 169</time_frame>
    <description>Pharmacokinetics of BMS-931699 derived from serum concentration versus time data; Ctrough = Trough level serum concentration of BMS-931699 at time point specified Pharmacokinetic Population: defined as all subjects who receive any study medication and have any available concentration-time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Biomarkers C3, C4</measure>
    <time_frame>At Day 85 and Day 169</time_frame>
    <description>Serum biomarkers C3, C4, anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-nuclear antibody (ANA) and other autoantibodies were measured from blood serum samples collected on Day 85 and Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Biomarkers: Anti-Nuclear Antibodies (ANA)</measure>
    <time_frame>At Day 85 and Day 169</time_frame>
    <description>Serum biomarkers C3, C4, anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-nuclear antibody (ANA) and other autoantibodies were measured from blood serum samples collected on Day 85 and Day 169. No anti-dsDNA data was available for this report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Term: Receptor Occupancy Over Time</measure>
    <time_frame>At Day 85 and Day 169</time_frame>
    <description>Percent CD4+ Receptor Occupancy and percent CD8+ Receptor Occupancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With BMS-931699 Induced Antibody Response Over Time Point Specified</measure>
    <time_frame>Day 169</time_frame>
    <description>Immunogenicity defined as positive for anti-drug antibodies post-baseline measurement if baseline missing or negative. If baseline is positive, then immunogenicity is defined as a positive post-baseline measurement with titer value 4 times greater than baseline. (A) all subjects with a laboratory reported positive antibody responses to BMS-931699 during the short-term double-blind treatment period are included. Overall: At least one positive sample relative to baseline during short-term double-blind and follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: HEMATOLOGY I</measure>
    <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
    <description>HEMATOLOGY I: ERYTHROCYTE/PLATELET ATTRIBUTES HEMOGLOBIN G/L L &lt; 0.85×PRE-RX; HEMATOCRIT VOL L &lt; 0.85×PRE-RX; PLATELET COUNT X10*9 C/L H &gt; 1.5×ULN (ULN = Upper Limit of Normal) IF PRE-RX IS MISSING OR &gt; 1.5×ULN PLATELET COUNT X10*9 C/L L &lt; 0.85×LLN (LLN = Lower Limit of Normal) IF PRE-RX IS MISSING OR &lt; 0.85×LLN IF PRE-RX &gt;= LLN OR &lt; 0.85×PRE-RX IF PRE-RX &lt; LLN; ERYTHROCYTES RBC X10*12 C/L L &lt; 0.85×PRE-RX HEMATOLOGY II QUANTITATIVE WBC : LEUKOCYTES X10*9 C/L H &gt; 1.2×ULN IF PRE-RX IS MISSING OR &gt; 1.2×ULN IF LLN &lt;= PRE-RX &lt;= ULN OR &gt; 1.5×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; LEUKOCYTES WBC X10*9 C/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF LLN &lt;= PRE-RX &lt;= ULN OR &lt; 0.85×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: HEMATOLOGY II</measure>
    <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
    <description>WBC DIFFERENTIAL COUNT: BASOPHILS (ABSOLUTE) X10*9 C/L H &gt; 0.4; BLASTS (ABSOLUTE) X10*9 C/L H &gt; 0; EOSINOPHILS (ABSOLUTE) EOSA X10*9 C/L H &gt; 0.75; LYMPHOCYTES (ABSOLUTE) X10*9 C/L H &gt; 7.5; LYMPHOCYTES (ABSOLUTE) X10*9 C/L L &lt; 0.75; MONOCYTES (ABSOLUTE) X10*9 C/L H &gt; 2; NEUTROPHILS (ABSOLUTE) X10*9 C/L L &lt; 1.5 IF PRE-RX IS MISSING OR &lt; 1.5 IF PRE-RX &gt;= 1.5 OR &lt; 0.85×PRE-RX IF PRE-RX &lt; 1.5; COAGULATION activated Partial thromboplastin time (APTT) SEC H &gt; 1.5×ULN; INTL NORMALIZED RATIO (INR) INR FRACTION H &gt; 1.5×ULN PROTHROMBIN TIME (PT) PT SEC H &gt; 1.5×ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests : LIVER FUNCTION TESTS</measure>
    <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
    <description>LIVER FUNCTION TESTS:ALKALINE PHOSPHATASE (ALP) ALP U/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN; ALANINE AMINOTRANSFERASE (ALT) ALT U/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN; ASPARTATE AMINOTRANSFERASE (AST) AST U/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN; BILIRUBIN, DIRECT UMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN G-GLUTAMYL TRANSFERASE (GGT) GGT U/L H &gt; 1.15×ULN IF PRE-RX IS MISSING OR &gt; 1.15×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN BILIRUBIN, TOTAL UMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: KIDNEY FUNCTION TESTS</measure>
    <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
    <description>KIDNEY FUNCTION TESTS:BLOOD UREA NITROGEN MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN CREATININE UMOL/L H &gt; 1.5×ULN IF PRE-RX IS MISSING OR &gt; 1.5×ULN IF PRE-RX &lt;= ULN OR &gt; 1.33×PRE-RX IF PRE-RX &gt; ULN GLOMERULAR FILTRATION RATE, CALC. ML/S/M*2 L &lt; 0.8×PRE-RX; UREA UREA MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests ELECTROLYTES 1</measure>
    <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
    <description>CALCIUM, TOTAL MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; CALCIUM, TOTAL MMOL/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN; CHLORIDE, SERUM MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; CHLORIDE, SERUM MMOL/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests: ELECTROLYTES 2</measure>
    <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
    <description>BICARBONATE MMOL/L H &gt; 1.2×ULN IF PRE-RX IS MISSING OR &gt; 1.2×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; BICARBONATE MMOL/L L &lt; 0.8×LLN IF PRE-RX IS MISSING OR &lt; 0.8×LLN IF PRE-RX &gt;= LLN OR &lt; 0.8×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN; POTASSIUM, SERUM MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; POTASSIUM, SERUM MMOL/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN; MAGNESIUM, SERUM MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN MAGNESIUM, SERUM MMOL/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests: ELECTROLYTES 3</measure>
    <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
    <description>SODIUM, SERUM MMOL/L H &gt; 1.05×ULN IF PRE-RX IS MISSING OR &gt; 1.05×ULN IF PRE-RX &lt;= ULN OR &gt; 1.05×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN SODIUM, SERUM MMOL/L L &lt; 0.95×LLN IF PRE-RX IS MISSING OR &lt; 0.95×LLN IF PRE-RX &gt;= LLN OR &lt; 0.95×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN PHOSPHORUS, INORGANIC PHOS MMOL/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN PHOSPHORUS, INORGANIC PHOS MMOL/L L &lt; 0.85×LLN IF PRE-RX IS MISSING OR &lt; 0.85×LLN IF PRE-RX &gt;=LLN OR &lt; 0.85×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 1</measure>
    <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
    <description>GLUCOSE TESTS:GLUCOSE, FASTING SERUM MMOL/L H &gt; 1.3×ULN IF PRE-RX IS MISSING OR &gt; 1.3×ULN IF PRE-RX &lt;= ULN OR &gt; 2×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN GLUCOSE, FASTING SERUM MMOL/L L &lt; 0.8×LLN IF PRE-RX IS MISSING OR &lt; 0.8×LLN IF PRE-RX &gt;= LLN OR &lt; 0.8×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN; PROTEIN TESTS:ALBUMIN G/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN PROTEIN, TOTAL G/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN PROTEIN, TOTAL G/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 2</measure>
    <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
    <description>OTHER CHEMISTRY TESTING LIPID TESTS: CHOLESTEROL, TOTAL (TC) MMOL/L H &gt; 1.2×ULN IF PRE-RX IS MISSING OR &gt; 1.2×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN TRIGLYCERIDES, FASTING MMOL/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.5×PRE-RX IF PRE-RX &gt; ULN PANCREATIC TESTS: AMYLASE, TOTAL U/L H &gt; 1.5×ULN; LIPASE, TOTAL (TURBIDIMETRIC ASSAY) U/L H &gt; 1.5×ULN; LIPASE, TOTAL (COLORIMETRIC ASSAY) U/L H &gt; 1.5×ULN; ENDOCRINE TESTS:CORTISOL, AM NMOL/L L &lt; 138 THYROID STIMULATING HORMONE (TSH) TSH MU/L H &gt; 1.5×ULN IF PRE-RX IS MISSING OR &gt; 1.5×ULN IF PRE-RX &lt;= ULN OR &gt; 2×PRE-RX IF PRE-RX &gt; ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 3</measure>
    <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
    <description>OTHER CHEMISTRY TESTING CARDIAC TESTS: CREATINE KINASE (CK) CK U/L H &gt; 1.5×ULN IF PRE-RX IS MISSING OR &gt; 1.5×ULN IF PRE-RX &lt;= ULN OR &gt; 1.5×PRE-RX IF PRE-RX &gt; ULN; TROPONIN-I, CARDIAC SPECIFIC UG/L H &gt; ULN; METABOLITE TESTS:URIC ACID URIC MMOL/L H &gt; 1.2×ULN IF PRE-RX IS MISSING OR &gt; 1.2×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN; CHEM TEST, MULTI INDICATIONS : LACTATE DEHYDROGENASE (LD) LD U/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.5×PRE-RX IF PRE-RX &gt; ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : IMMUNOLOGY</measure>
    <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
    <description>IMMUNE ACTIVATION MARKERS:C-REACTIVE PROTEIN (CRP) CRP MG/L H &gt; 1.5×ULN; CRP, HIGH SENSITIVITY MG/L H &gt; 1.5×ULN;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : URINALYSIS</measure>
    <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
    <description>QUALITATIVE URINE CHEMISTRY: BLOOD, URINE N/A H &gt;= 2 IF PRE-RX IS MISSING OR &gt;= 2 IF PRE-RX &lt; 1 OR &gt;= 2×PRE-RX IF PRE-RX &gt;= 1 GLUCOSE, URINE N/A H &gt;= 1 IF PRE-RX IS MISSING OR &gt;= 1 IF PRE-RX &lt; 1 OR &gt;= 2×PRE-RX IF PRE-RX &gt;= 1 PROTEIN, URINE UNKNOWN H &gt;= 2 IF PRE-RX IS MISSING OR &gt;= 2 IF PRE-RX &lt; 1 OR &gt;= 2×PRE-RX IF PRE-RX &gt;= 1 URINALYSIS II URINE WBC + RBC ; RBC, URINE HPF H &gt;= 2 IF PRE-RX IS MISSING OR &gt;= 2 IF PRE-RX &lt; 2 OR &gt;= 4 IF PRE-RX &gt;= 2 WBC, URINE HPF H &gt;= 2 IF PRE-RX IS MISSING OR &gt;= 2 IF PRE-RX &lt; 2 OR &gt;= 4 IF PRE-RX &gt;= 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the SLEDAI-2K Score of SLE Activity on Day 85 and Day 169</measure>
    <time_frame>At baseline, Day 85 and Day 169</time_frame>
    <description>Systemic Lupus Erythematosus Disease Activity Index, SLEDAI; Version 2000, also known as SLEDAI-2K. The SLEDAI-2K score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician Global Assessment of Disease Activity (MDGA) on Day 85 and Day 169</measure>
    <time_frame>At baseline, Day 85 and Day 169</time_frame>
    <description>Physician Global Assessment of Arthritis was measured by asking the physician to assess the participant's current arthritis disease activity by placing a vertical line on a 0 to 100 millimeter (mm) visual analog scale (VAS), where 0 mm = very good and 100 mm = very bad.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">730</enrollment>
  <condition>Lupus</condition>
  <arm_group>
    <arm_group_label>Experimental:Arm A: BMS-931699</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.5mg subcutaneous (SC) injection Weekly dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental:Arm B: BMS-931699</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.5mg SC injection Every other Week dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental:Arm C: BMS-931699</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg SC injection Every other Week dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental:Arm D: BMS-931699</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.25mg SC injection Every other Week dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Arm E: Placebo matching BMS-931699</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0mg SC injection Weekly dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-931699</intervention_name>
    <arm_group_label>Experimental:Arm A: BMS-931699</arm_group_label>
    <arm_group_label>Experimental:Arm B: BMS-931699</arm_group_label>
    <arm_group_label>Experimental:Arm C: BMS-931699</arm_group_label>
    <arm_group_label>Experimental:Arm D: BMS-931699</arm_group_label>
    <other_name>lulizumab pegol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching BMS-931699</intervention_name>
    <arm_group_label>Placebo Comparator: Arm E: Placebo matching BMS-931699</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Male or female aged between 18 to 70 (included)

          -  Diagnosed with active systemic lupus erythematosus by a doctor

          -  Disease must be in patient's joints or on the skin at a minimum

          -  Taking other medications is allowed but some are excluded

        Exclusion Criteria:

          -  Diagnosed with active lupus nephritis, multiple sclerosis or rheumatoid arthritis

          -  Diagnosed with active tuberculosis or an ongoing infection with a bacteria or a virus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Associates Of North Alabama, P.C.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Jude Hospital Yorba Linda</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valerius Med Group &amp; Res Ctr Of Greater Long Beach, Inc.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Rheumatology, Immunology And Arthritis</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Center</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684-3176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jefrey D. Lieberman, Md., Pc</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coeur D'Alene Arthrit Clin</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814-2644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, Llc</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207-5150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Med. Center Div. Of Gastroenterology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Research Collaboration, Llc</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102-2631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Lij Health System</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Feinstein Institute For Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint and Muscle Medical Care and Research Institute (JMMCRI)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pmg Research Of Salisbury</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Penn Rheumatology Associates, P.C.</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny-Singer Research Institute (Asri)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1431</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General De Agudos J.M. Ramos Mejia</name>
      <address>
        <city>Ciudad Autonoma De Buenos Aire</city>
        <state>Buenos Aires</state>
        <zip>1221</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto De Investigaciones Clinicas De Mar Del Plata</name>
      <address>
        <city>Mar Del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Asistencia Reumatologica Integral</name>
      <address>
        <city>San Fernando</city>
        <state>Buenos Aires</state>
        <zip>1646</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica De Reumatologia</name>
      <address>
        <city>Rosario</city>
        <state>Santa FE</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Consultora Integral de Salud SRL</name>
      <address>
        <city>Cordoba</city>
        <zip>5004</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicos Especializados em Reumatologia SER</name>
      <address>
        <city>Savaldor</city>
        <state>Bahia</state>
        <zip>40150-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cip Pesquisas Medicas</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Mineiro De Pesquisa</name>
      <address>
        <city>Juiz de Fora</city>
        <state>Minas Gerais</state>
        <zip>36010570</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Varginha</name>
      <address>
        <city>Varginha</city>
        <state>Minas Gerais</state>
        <zip>37006-710</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edumed - Educacao em Saude S/S LTDA</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80440-210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMK Servicos Medicos S S Ltda</name>
      <address>
        <city>Porto Alegre</city>
        <state>RIO Grande DO SUL</state>
        <zip>90480-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPCLIN Centro de Pesquisas Clinicas LTDA</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01244-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lar Escola AACD</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04032-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karma Clinical Trials Inc.</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 4Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre De Recherche Musculo-Squelettique</name>
      <address>
        <city>Trois-rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec Research Centre</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro De Estudios Reumatologicos</name>
      <address>
        <city>Santiago De Chile</city>
        <state>Metropolitana</state>
        <zip>7501126</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Borja Arriaran</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>8360156</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riesgo De Fractura</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servimed E.U</name>
      <address>
        <city>Bucaramanga</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica De La Costa</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin</city>
        <zip>MEDELLIN</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinsche Universitaetsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetshautklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg - Universitaet</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infektologiai-Hepatologiai Osztaly</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgyogyaszati Klinika</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Anna</name>
      <address>
        <city>Cona - Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <zip>2608677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>8128582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>8078555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>0608604</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>0608648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kanazawa-shi</city>
        <state>Ishikawa</state>
        <zip>9208641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>9808574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sasebo-shi</city>
        <state>Nagasaki</state>
        <zip>8571195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shimotsuke-shi</city>
        <state>Tochigi</state>
        <zip>3290498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>1138655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1048560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fuchu</city>
        <state>Tokyo</state>
        <zip>1838524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>1738610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>1538515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <zip>1608582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>07345</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tripoli</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CINTRE - Centro de investigacion y tratamiento reumatologico, S.C.</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Fededral</state>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto para el DeSarrollo Integral de la Salud S de RL de CV</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Medico de Reumatologia Dr.Jesus Alberto Lopez Garcia</name>
      <address>
        <city>León</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral En Reumatologia Sa De Cv</name>
      <address>
        <city>Guadalajara, Jalisco</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Investigacion en Reumatologia y Obesidad S.C.</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Radiodiagnostico Computarizado Medico de Tabasco S.A. de C.V.</name>
      <address>
        <city>Villahermosa</city>
        <state>Tabasco</state>
        <zip>86190</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional De Ciencias Medicas Y Nutricion S.Z.</name>
      <address>
        <city>Distrito Federal</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C.</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78213</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Reumatologica Las Americas, S.C. P.</name>
      <address>
        <city>Yucatan</city>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Anglo Americana</name>
      <address>
        <city>Lima</city>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Cayetano Heredia</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto De Ginecologia Y Reproduccion Inv. Clinical Sac</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medyczne Centrum Hetmanska Indywidualna Spec. Praktyka Lekar</name>
      <address>
        <city>Poznan</city>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>00-465</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sf. Maria Clinical Hospital,Bucharest</name>
      <address>
        <city>Bucharest</city>
        <zip>011192</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Recuperare Iasi</name>
      <address>
        <city>Iasi</city>
        <zip>700661</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St Petersburg</city>
        <zip>191124</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tolyatti</city>
        <zip>445039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cape Town</city>
        <state>Western CAPE</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stellenbosch</city>
        <state>Western CAPE</state>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Univer 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya De Malaga</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Meixoeiro</name>
      <address>
        <city>Vigo</city>
        <zip>36241</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Qatar</country>
  </removed_countries>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2014</study_first_posted>
  <results_first_submitted>October 25, 2018</results_first_submitted>
  <results_first_submitted_qc>January 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 4, 2019</results_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 3, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02265744/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02265744/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>730 participants were enrolled and 349 were randomized. 3 were randomized but not treated.Of the 381 who were not randomized,3 had an adverse event, 16 withdrew consent, 1 was lost to follow-up, 339 did not meet study entry criteria and 22 due to other reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
          <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
        </group>
        <group group_id="P2">
          <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
          <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
        </group>
        <group group_id="P3">
          <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
          <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
        </group>
        <group group_id="P4">
          <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
          <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
        </group>
        <group group_id="P5">
          <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
          <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="70"/>
                <participants group_id="P5" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Poor/Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant request to discontinue</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not provided by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
          <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
        </group>
        <group group_id="B2">
          <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
          <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
        </group>
        <group group_id="B3">
          <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
          <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
        </group>
        <group group_id="B4">
          <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
          <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
        </group>
        <group group_id="B5">
          <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
          <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="68"/>
            <count group_id="B4" value="70"/>
            <count group_id="B5" value="71"/>
            <count group_id="B6" value="346"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>All randomized and treated participants</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="68"/>
                    <count group_id="B4" value="70"/>
                    <count group_id="B5" value="71"/>
                    <count group_id="B6" value="346"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.0" lower_limit="18" upper_limit="64"/>
                    <measurement group_id="B2" value="39.1" lower_limit="19" upper_limit="68"/>
                    <measurement group_id="B3" value="41.9" lower_limit="19" upper_limit="69"/>
                    <measurement group_id="B4" value="38.0" lower_limit="19" upper_limit="69"/>
                    <measurement group_id="B5" value="40.6" lower_limit="18" upper_limit="68"/>
                    <measurement group_id="B6" value="40.2" lower_limit="18" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <population>All randomized and treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Females &lt;= 50 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="65"/>
                    <count group_id="B4" value="66"/>
                    <count group_id="B5" value="65"/>
                    <count group_id="B6" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Females &gt; 50 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="67"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="65"/>
                    <count group_id="B4" value="66"/>
                    <count group_id="B5" value="65"/>
                    <count group_id="B6" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="68"/>
                    <count group_id="B4" value="70"/>
                    <count group_id="B5" value="71"/>
                    <count group_id="B6" value="346"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="65"/>
                    <measurement group_id="B6" value="329"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="68"/>
                    <count group_id="B4" value="70"/>
                    <count group_id="B5" value="71"/>
                    <count group_id="B6" value="346"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="63"/>
                    <measurement group_id="B6" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="68"/>
                    <count group_id="B4" value="70"/>
                    <count group_id="B5" value="71"/>
                    <count group_id="B6" value="346"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieve a BICLA Response (BICLA Response Rate) at Day 169</title>
        <description>The British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) is a measure of systemic lupus erythematosus (SLE) response. BICLA is defined as: British Isle Lupus Assessment Group improvement, defined as BILAG As at Baseline improved to B/C/D, and BILAG Bs at baseline improved to C/D, and no BILAG worsening in other BILAG organ systems such that there are no new BILAG As or greater than 1 new BILAG B; and no worsening in the SLEDAI-2K total score compared to Baseline (defined as no increase in SLEDAI total score); and no worsening in the physician's global assessment (MDGA) of disease activity (&quot;no worsening&quot; is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline.</description>
        <time_frame>At Day 169</time_frame>
        <population>All Randomized and Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieve a BICLA Response (BICLA Response Rate) at Day 169</title>
          <description>The British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) is a measure of systemic lupus erythematosus (SLE) response. BICLA is defined as: British Isle Lupus Assessment Group improvement, defined as BILAG As at Baseline improved to B/C/D, and BILAG Bs at baseline improved to C/D, and no BILAG worsening in other BILAG organ systems such that there are no new BILAG As or greater than 1 new BILAG B; and no worsening in the SLEDAI-2K total score compared to Baseline (defined as no increase in SLEDAI total score); and no worsening in the physician's global assessment (MDGA) of disease activity (&quot;no worsening&quot; is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline.</description>
          <population>All Randomized and Treated participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" lower_limit="49.7" upper_limit="69.1"/>
                    <measurement group_id="O2" value="63.2" lower_limit="53.6" upper_limit="72.9"/>
                    <measurement group_id="O3" value="57.4" lower_limit="47.5" upper_limit="67.2"/>
                    <measurement group_id="O4" value="58.6" lower_limit="48.9" upper_limit="68.3"/>
                    <measurement group_id="O5" value="59.2" lower_limit="49.6" upper_limit="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9745</p_value>
            <method>Chi-squared</method>
            <method_desc>Nominal p-values that are not adjusted for multiplicity.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6217</p_value>
            <method>Chi-squared</method>
            <method_desc>Nominal p-values that are not adjusted for multiplicity.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8295</p_value>
            <method>Chi-squared</method>
            <method_desc>Nominal p-values that are not adjusted for multiplicity.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9439</p_value>
            <method>Chi-squared</method>
            <method_desc>Nominal p-values that are not adjusted for multiplicity.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Meet Response Criteria for the SLE Responder Index : SRI(4), SRI(5) and SRI(6) at Day 169</title>
        <description>SRI is the Systemic Lupus Erythematosus Responder Index. An SRI(4) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 4 points AND (a)no worsening in the physician's global assessment (MDGA) of disease activity (&quot;no worsening&quot; is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline) AND (b) no new BILAG-2004 Index A organ system score AND (c)no more than one new or worsening BILAG-2004 Index B organ system scores.
An SRI(5) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 5 points AND (a) AND (b) AND (c).
An SRI(6) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 6 points AND (a) AND (b) AND (c) The outcomes are better in increasing order from SRI(4) to SRI(5) to SRI(6)</description>
        <time_frame>At Day 169</time_frame>
        <population>All randomized and treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Meet Response Criteria for the SLE Responder Index : SRI(4), SRI(5) and SRI(6) at Day 169</title>
          <description>SRI is the Systemic Lupus Erythematosus Responder Index. An SRI(4) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 4 points AND (a)no worsening in the physician's global assessment (MDGA) of disease activity (&quot;no worsening&quot; is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline) AND (b) no new BILAG-2004 Index A organ system score AND (c)no more than one new or worsening BILAG-2004 Index B organ system scores.
An SRI(5) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 5 points AND (a) AND (b) AND (c).
An SRI(6) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 6 points AND (a) AND (b) AND (c) The outcomes are better in increasing order from SRI(4) to SRI(5) to SRI(6)</description>
          <population>All randomized and treated participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SRI (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.1" lower_limit="45.2" upper_limit="64.9"/>
                    <measurement group_id="O2" value="48.5" lower_limit="38.6" upper_limit="58.5"/>
                    <measurement group_id="O3" value="39.7" lower_limit="29.9" upper_limit="49.5"/>
                    <measurement group_id="O4" value="44.3" lower_limit="34.5" upper_limit="54.1"/>
                    <measurement group_id="O5" value="49.3" lower_limit="39.5" upper_limit="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRI (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7" lower_limit="28.1" upper_limit="47.3"/>
                    <measurement group_id="O2" value="29.4" lower_limit="20.3" upper_limit="38.5"/>
                    <measurement group_id="O3" value="27.9" lower_limit="19.0" upper_limit="36.9"/>
                    <measurement group_id="O4" value="31.4" lower_limit="22.3" upper_limit="40.6"/>
                    <measurement group_id="O5" value="33.8" lower_limit="24.6" upper_limit="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRI (6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7" lower_limit="28.1" upper_limit="47.3"/>
                    <measurement group_id="O2" value="26.5" lower_limit="17.7" upper_limit="35.3"/>
                    <measurement group_id="O3" value="27.9" lower_limit="19.0" upper_limit="36.9"/>
                    <measurement group_id="O4" value="31.4" lower_limit="22.3" upper_limit="40.6"/>
                    <measurement group_id="O5" value="33.8" lower_limit="24.6" upper_limit="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Meet Response Criteria for the SLE Responder Index: SRI(4), SRI(5) and SRI(6) at Day 85</title>
        <description>SRI is the Systemic Lupus Erythematosus Responder Index. An SRI(4) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 4 points AND (a)no worsening in the physician's global assessment (MDGA) of disease activity (&quot;no worsening&quot; is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline) AND (b) no new BILAG-2004 Index A organ system score AND (c)no more than one new or worsening BILAG-2004 Index B organ system scores.
An SRI(5) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 5 points AND (a) AND (b) AND (c).
An SRI(6) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 6 points AND (a) AND (b) AND (c) The outcomes are better in increasing order from SRI(4) to SRI(5) to SRI(6)</description>
        <time_frame>At Day 85</time_frame>
        <population>All Randomized and Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Meet Response Criteria for the SLE Responder Index: SRI(4), SRI(5) and SRI(6) at Day 85</title>
          <description>SRI is the Systemic Lupus Erythematosus Responder Index. An SRI(4) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 4 points AND (a)no worsening in the physician's global assessment (MDGA) of disease activity (&quot;no worsening&quot; is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline) AND (b) no new BILAG-2004 Index A organ system score AND (c)no more than one new or worsening BILAG-2004 Index B organ system scores.
An SRI(5) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 5 points AND (a) AND (b) AND (c).
An SRI(6) Response is defined as a reduction in Day 1 SLEDAI-2K disease activity score of ≥ 6 points AND (a) AND (b) AND (c) The outcomes are better in increasing order from SRI(4) to SRI(5) to SRI(6)</description>
          <population>All Randomized and Treated participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SRI (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" lower_limit="39.4" upper_limit="59.2"/>
                    <measurement group_id="O2" value="48.5" lower_limit="38.6" upper_limit="58.5"/>
                    <measurement group_id="O3" value="41.2" lower_limit="31.4" upper_limit="51.0"/>
                    <measurement group_id="O4" value="47.1" lower_limit="37.3" upper_limit="57.0"/>
                    <measurement group_id="O5" value="43.7" lower_limit="34.0" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRI (5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" lower_limit="20.0" upper_limit="38.0"/>
                    <measurement group_id="O2" value="32.4" lower_limit="23.0" upper_limit="41.7"/>
                    <measurement group_id="O3" value="25.0" lower_limit="16.4" upper_limit="33.6"/>
                    <measurement group_id="O4" value="31.4" lower_limit="22.3" upper_limit="40.6"/>
                    <measurement group_id="O5" value="28.2" lower_limit="19.4" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRI (6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" lower_limit="20.0" upper_limit="38.0"/>
                    <measurement group_id="O2" value="30.9" lower_limit="21.7" upper_limit="40.1"/>
                    <measurement group_id="O3" value="25.0" lower_limit="16.4" upper_limit="33.6"/>
                    <measurement group_id="O4" value="31.4" lower_limit="22.3" upper_limit="40.6"/>
                    <measurement group_id="O5" value="26.8" lower_limit="18.1" upper_limit="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With BICLA Response (BICLA Response Rate) at Day 85</title>
        <description>BICLA is defined as: British Isle Lupus Assessment Group improvement, defined as BILAG As at Baseline improved to B/C/D, and BILAG Bs at baseline improved to C/D, and no BILAG worsening in other BILAG organ systems such that there are no new BILAG As or greater than 1 new BILAG B; and no worsening in the SLEDAI-2K total score compared to Baseline (defined as no increase in SLEDAI total score); and no worsening in the physician's global assessment (MDGA) of disease activity (&quot;no worsening&quot; is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline; No changes in concomitant medications according to the following criteria: No increase of or addition of a new immunosuppressant agent (azathioprine,mycophenolic acid/mycophenolate mofetil, methotrexate, anti-malarial, leflunomide) over baseline levels; No increase in corticosteroid dose above baseline level outside of those allowed per protocol.</description>
        <time_frame>At Day 85</time_frame>
        <population>All Randomized and Treated Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With BICLA Response (BICLA Response Rate) at Day 85</title>
          <description>BICLA is defined as: British Isle Lupus Assessment Group improvement, defined as BILAG As at Baseline improved to B/C/D, and BILAG Bs at baseline improved to C/D, and no BILAG worsening in other BILAG organ systems such that there are no new BILAG As or greater than 1 new BILAG B; and no worsening in the SLEDAI-2K total score compared to Baseline (defined as no increase in SLEDAI total score); and no worsening in the physician's global assessment (MDGA) of disease activity (&quot;no worsening&quot; is defined as less than 10% worsening, equivalent to a 10mm increase on a 100mm visual analog scale [VAS]) compared to Baseline; No changes in concomitant medications according to the following criteria: No increase of or addition of a new immunosuppressant agent (azathioprine,mycophenolic acid/mycophenolate mofetil, methotrexate, anti-malarial, leflunomide) over baseline levels; No increase in corticosteroid dose above baseline level outside of those allowed per protocol.</description>
          <population>All Randomized and Treated Participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" lower_limit="60.5" upper_limit="78.7"/>
                    <measurement group_id="O2" value="64.7" lower_limit="55.2" upper_limit="74.2"/>
                    <measurement group_id="O3" value="57.4" lower_limit="47.5" upper_limit="67.2"/>
                    <measurement group_id="O4" value="57.1" lower_limit="47.4" upper_limit="66.9"/>
                    <measurement group_id="O5" value="54.9" lower_limit="45.2" upper_limit="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CLASI Score at Day 85 and Day 169</title>
        <description>Mean change from baseline, CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index. Scores can range from 0 to 70 with higher scores denoting greater disease activity or damage.</description>
        <time_frame>At Day 85 and Day 169</time_frame>
        <population>All Randomized and Treated Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CLASI Score at Day 85 and Day 169</title>
          <description>Mean change from baseline, CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index. Scores can range from 0 to 70 with higher scores denoting greater disease activity or damage.</description>
          <population>All Randomized and Treated Subjects</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="3.107"/>
                    <measurement group_id="O2" value="-3.20" spread="4.718"/>
                    <measurement group_id="O3" value="-1.69" spread="2.319"/>
                    <measurement group_id="O4" value="-1.82" spread="4.515"/>
                    <measurement group_id="O5" value="-3.11" spread="4.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.17" spread="4.387"/>
                    <measurement group_id="O2" value="-3.78" spread="5.555"/>
                    <measurement group_id="O3" value="-2.47" spread="2.824"/>
                    <measurement group_id="O4" value="-2.94" spread="4.897"/>
                    <measurement group_id="O5" value="-3.57" spread="4.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Improvement of &gt;4 or a Decrease of &gt;50% From Baseline in Their Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Score</title>
        <description>Mean change from baseline, CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index. Scores can range from 0 to 70 with higher scores denoting greater disease activity or damage.</description>
        <time_frame>At Day 85 and Day 169</time_frame>
        <population>All randomized and treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Improvement of &gt;4 or a Decrease of &gt;50% From Baseline in Their Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Score</title>
          <description>Mean change from baseline, CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index. Scores can range from 0 to 70 with higher scores denoting greater disease activity or damage.</description>
          <population>All randomized and treated participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" lower_limit="29.1" upper_limit="49.6"/>
                    <measurement group_id="O2" value="46.9" lower_limit="36.6" upper_limit="57.1"/>
                    <measurement group_id="O3" value="34.5" lower_limit="24.2" upper_limit="44.7"/>
                    <measurement group_id="O4" value="36.1" lower_limit="26.0" upper_limit="46.2"/>
                    <measurement group_id="O5" value="42.4" lower_limit="32.4" upper_limit="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Arthritis, as Assessed by American College of Rheumatology (ACR) 28-joint Count of Tender and Swollen Joints on Day 85 and Day 169</title>
        <description>Mean Change from Baseline Over Time; Measured by Disease Activity Score 28: A single score on a continuous scale (0-9.4). The level of RA disease activity can be interpreted as low (DAS28 &lt;=3.2),moderate (3.2 &lt; DAS28 &lt;=5.1), or as high disease activity (DAS28 &gt; 5.1)</description>
        <time_frame>At baseline, Day 85 and Day 169</time_frame>
        <population>All Randomized and Treated Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Arthritis, as Assessed by American College of Rheumatology (ACR) 28-joint Count of Tender and Swollen Joints on Day 85 and Day 169</title>
          <description>Mean Change from Baseline Over Time; Measured by Disease Activity Score 28: A single score on a continuous scale (0-9.4). The level of RA disease activity can be interpreted as low (DAS28 &lt;=3.2),moderate (3.2 &lt; DAS28 &lt;=5.1), or as high disease activity (DAS28 &gt; 5.1)</description>
          <population>All Randomized and Treated Participants</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.63" spread="4.719"/>
                    <measurement group_id="O2" value="-4.63" spread="5.311"/>
                    <measurement group_id="O3" value="-4.75" spread="4.985"/>
                    <measurement group_id="O4" value="-4.42" spread="5.626"/>
                    <measurement group_id="O5" value="-3.84" spread="4.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in BILAG-2004 Score of Systemic Lupus Erythematosus (SLE) Activity on Day 85 and Day 169</title>
        <description>Overall British Isles Lupus Assessment Group-2004 score, BILAG Scores: A=Severe disease activity, B=Moderate disease activity, C=Mild disease, D=Inactive disease but previously affected, E=System never involved.The categories are converted to a numeric score (A=9, B=3, C=1, D=0, E=0) and treated as a continuous variable. Higher score= more severe disease activity.</description>
        <time_frame>At baseline, Day 85 and Day 169</time_frame>
        <population>All randomized and treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BILAG-2004 Score of Systemic Lupus Erythematosus (SLE) Activity on Day 85 and Day 169</title>
          <description>Overall British Isles Lupus Assessment Group-2004 score, BILAG Scores: A=Severe disease activity, B=Moderate disease activity, C=Mild disease, D=Inactive disease but previously affected, E=System never involved.The categories are converted to a numeric score (A=9, B=3, C=1, D=0, E=0) and treated as a continuous variable. Higher score= more severe disease activity.</description>
          <population>All randomized and treated participants</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BILAG-2004 Score Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.31" spread="7.480"/>
                    <measurement group_id="O2" value="-8.83" spread="7.749"/>
                    <measurement group_id="O3" value="-7.07" spread="7.299"/>
                    <measurement group_id="O4" value="-8.66" spread="6.598"/>
                    <measurement group_id="O5" value="-7.94" spread="8.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BILAG-2004 Score Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.50" spread="6.983"/>
                    <measurement group_id="O2" value="-10.46" spread="7.808"/>
                    <measurement group_id="O3" value="-8.98" spread="6.719"/>
                    <measurement group_id="O4" value="-9.73" spread="5.478"/>
                    <measurement group_id="O5" value="-9.78" spread="7.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Corticosteroid and Immunosuppressant Use</title>
        <description>Percent of participants requiring use of corticosteroids and mmunosuppressants use over time</description>
        <time_frame>Up to one day prior to the first dose of long-term extension period or up to 42 days post last short-term dose date, which ever is earlier</time_frame>
        <population>All randomized and treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Corticosteroid and Immunosuppressant Use</title>
          <description>Percent of participants requiring use of corticosteroids and mmunosuppressants use over time</description>
          <population>All randomized and treated participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Corticosteroids: Oral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9"/>
                    <measurement group_id="O2" value="82.4"/>
                    <measurement group_id="O3" value="86.8"/>
                    <measurement group_id="O4" value="84.3"/>
                    <measurement group_id="O5" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corticosteroids: Oral inhalation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunosuppressant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4"/>
                    <measurement group_id="O2" value="63.2"/>
                    <measurement group_id="O3" value="38.2"/>
                    <measurement group_id="O4" value="51.4"/>
                    <measurement group_id="O5" value="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunosuppressant Azathioprine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2"/>
                    <measurement group_id="O2" value="29.4"/>
                    <measurement group_id="O3" value="14.7"/>
                    <measurement group_id="O4" value="28.6"/>
                    <measurement group_id="O5" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunosuppressant Methotrexate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1"/>
                    <measurement group_id="O2" value="35.3"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="24.3"/>
                    <measurement group_id="O5" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Pre-established Events of Special Interest</title>
        <description>Although there are no identified risks for BMS-931699, BMS has developed a list of events of special interest for the BMS-931699 program based on the known biologic class effects, the mechanism of action of BMS-931699, overall potential consequences of mmunosuppression, and preliminary data from unblinded clinical trials. Event categories of special interest for this study may include, but are not limited to: Infections, Autoimmunity, Malignancies, Injection-related reactions</description>
        <time_frame>On or after the first dose date of short-term study medication and up to 42 days post last short-term dose date or up to the day prior to the first dose of long-term extension period, whichever is earlier</time_frame>
        <population>All treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Pre-established Events of Special Interest</title>
          <description>Although there are no identified risks for BMS-931699, BMS has developed a list of events of special interest for the BMS-931699 program based on the known biologic class effects, the mechanism of action of BMS-931699, overall potential consequences of mmunosuppression, and preliminary data from unblinded clinical trials. Event categories of special interest for this study may include, but are not limited to: Infections, Autoimmunity, Malignancies, Injection-related reactions</description>
          <population>All treated subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs of Malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs of Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Events of Autoimmunity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most Common Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="59"/>
                    <measurement group_id="O5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Events of Local Injection Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinically Significant Changes in Vital Signs:Heart Rate</title>
        <description>HEART RATE (HR) Beats per min (BPM): HR &gt; 100 AND CHANGE FROM BASELINE &gt; 30 OR HR &lt; 55 AND CHANGE FROM BASELINE &lt; -15</description>
        <time_frame>At Day 85 and Day 169</time_frame>
        <population>All Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Significant Changes in Vital Signs:Heart Rate</title>
          <description>HEART RATE (HR) Beats per min (BPM): HR &gt; 100 AND CHANGE FROM BASELINE &gt; 30 OR HR &lt; 55 AND CHANGE FROM BASELINE &lt; -15</description>
          <population>All Treated participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HEART RATE (BPM) SITTING</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="2.9"/>
                    <measurement group_id="O4" value="2.9"/>
                    <measurement group_id="O5" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEART RATE (BPM) STANDING</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="7.4"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEART RATE (BPM) SUPINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinically Significant Changes in Vital Signs: Systolic and Diastolic Blood Pressure</title>
        <description>SYSTOLIC BLOOD PRESSURE (SYSBP) (MMHG); SYSBP &gt; 140 AND CHANGE FROM BASELINE &gt; 20 OR SYSBP &lt; 90 AND CHANGE FROM BASELINE &lt; -20; DIASTOLIC BLOOD PRESSURE (DIABP) &gt; 90 AND CHANGE FROM BASELINE &gt; 10 OR DIABP &lt; 55 AND CHANGE FROM BASELINE &lt; -10;</description>
        <time_frame>At Day 85 and Day 169</time_frame>
        <population>All Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Significant Changes in Vital Signs: Systolic and Diastolic Blood Pressure</title>
          <description>SYSTOLIC BLOOD PRESSURE (SYSBP) (MMHG); SYSBP &gt; 140 AND CHANGE FROM BASELINE &gt; 20 OR SYSBP &lt; 90 AND CHANGE FROM BASELINE &lt; -20; DIASTOLIC BLOOD PRESSURE (DIABP) &gt; 90 AND CHANGE FROM BASELINE &gt; 10 OR DIABP &lt; 55 AND CHANGE FROM BASELINE &lt; -10;</description>
          <population>All Treated participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SYSTOLIC BLOOD PRESSURE (MMHG) SITTING</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="11.6"/>
                    <measurement group_id="O3" value="10.3"/>
                    <measurement group_id="O4" value="10.0"/>
                    <measurement group_id="O5" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYSTOLIC BLOOD PRESSURE (MMHG) STANDING</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="14.5"/>
                    <measurement group_id="O3" value="8.8"/>
                    <measurement group_id="O4" value="11.4"/>
                    <measurement group_id="O5" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYSTOLIC BLOOD PRESSURE (MMHG) SUPINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIASTOLIC BLOOD PRESSURE (MM HG) SITTING</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="26.1"/>
                    <measurement group_id="O3" value="11.8"/>
                    <measurement group_id="O4" value="17.1"/>
                    <measurement group_id="O5" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIASTOLIC BLOOD PRESSURE (MM HG) STANDING</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="21.4"/>
                    <measurement group_id="O5" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DIASTOLIC BLOOD PRESSURE (MM HG) SUPINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinically Significant Changes in Vital Signs: Respiration Rate</title>
        <description>RESPIRATION RATE (RESP) (PER MIN) RESP &gt; 16 OR RESP CHANGE FROM BASELINE &gt; 10</description>
        <time_frame>At Day 85 and Day 169</time_frame>
        <population>All Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Significant Changes in Vital Signs: Respiration Rate</title>
          <description>RESPIRATION RATE (RESP) (PER MIN) RESP &gt; 16 OR RESP CHANGE FROM BASELINE &gt; 10</description>
          <population>All Treated participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4"/>
                    <measurement group_id="O2" value="85.5"/>
                    <measurement group_id="O3" value="75.0"/>
                    <measurement group_id="O4" value="70.0"/>
                    <measurement group_id="O5" value="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinically Significant Changes in Vital Signs: Temperature</title>
        <description>TEMPERATURE (TEMP) (C) TEMP &gt; 38.3 OR TEMP CHANGE FROM BASELINE &gt; 1.6</description>
        <time_frame>At Day 85 and Day 169</time_frame>
        <population>All Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Significant Changes in Vital Signs: Temperature</title>
          <description>TEMPERATURE (TEMP) (C) TEMP &gt; 38.3 OR TEMP CHANGE FROM BASELINE &gt; 1.6</description>
          <population>All Treated participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="1.4"/>
                    <measurement group_id="O5" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities</title>
        <description>QTc (corrected QT) Fridericia, PR Interval, QRS Interval and Change from baseline in QTCF</description>
        <time_frame>Up to 42 days post last dose of short-term double-blind study medication or up to the day prior to the start of long-term extension period, whichever is earlier.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities</title>
          <description>QTc (corrected QT) Fridericia, PR Interval, QRS Interval and Change from baseline in QTCF</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTC Fredericia (msec) &lt;= 450</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTC Fredericia (msec) 450&lt; To &lt;= 480</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTC Fredericia (msec) 480 &lt; to &lt;= 500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTC Fredericia (msec) &gt; 500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval (msec) &lt;= 200</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval (msec) &gt; 200</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval (msec) &lt;= 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval (msec) &gt; 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline in QTCF (msec) &lt;= 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="55"/>
                    <measurement group_id="O5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline in QTCF (msec) 30 To &lt;= 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline in QTCF (msec) &gt; 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ctrough: Trough Level Serum Concentration of BMS-931699 at Time Point Specified</title>
        <description>Pharmacokinetics of BMS-931699 derived from serum concentration versus time data; Ctrough = Trough level serum concentration of BMS-931699 at time point specified Pharmacokinetic Population: defined as all subjects who receive any study medication and have any available concentration-time data.</description>
        <time_frame>Day 169</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Ctrough: Trough Level Serum Concentration of BMS-931699 at Time Point Specified</title>
          <description>Pharmacokinetics of BMS-931699 derived from serum concentration versus time data; Ctrough = Trough level serum concentration of BMS-931699 at time point specified Pharmacokinetic Population: defined as all subjects who receive any study medication and have any available concentration-time data.</description>
          <population>Pharmacokinetic population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2040" spread="945.57"/>
                    <measurement group_id="O2" value="640.8" spread="436.35"/>
                    <measurement group_id="O3" value="207.1" spread="149.53"/>
                    <measurement group_id="O4" value="62.2" spread="56.83"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Biomarkers C3, C4</title>
        <description>Serum biomarkers C3, C4, anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-nuclear antibody (ANA) and other autoantibodies were measured from blood serum samples collected on Day 85 and Day 169</description>
        <time_frame>At Day 85 and Day 169</time_frame>
        <population>All Treated participants with at Least One Post-Treatment Biomarker Measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Biomarkers C3, C4</title>
          <description>Serum biomarkers C3, C4, anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-nuclear antibody (ANA) and other autoantibodies were measured from blood serum samples collected on Day 85 and Day 169</description>
          <population>All Treated participants with at Least One Post-Treatment Biomarker Measurement</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C3, Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.068" spread="0.3405"/>
                    <measurement group_id="O2" value="1.029" spread="0.3265"/>
                    <measurement group_id="O3" value="0.990" spread="0.3318"/>
                    <measurement group_id="O4" value="1.028" spread="0.3149"/>
                    <measurement group_id="O5" value="0.991" spread="0.2641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3, Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.037" spread="0.3024"/>
                    <measurement group_id="O2" value="1.014" spread="0.3428"/>
                    <measurement group_id="O3" value="1.030" spread="0.3225"/>
                    <measurement group_id="O4" value="1.083" spread="0.3124"/>
                    <measurement group_id="O5" value="0.986" spread="0.3005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3, Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.045" spread="0.3405"/>
                    <measurement group_id="O2" value="1.010" spread="0.3557"/>
                    <measurement group_id="O3" value="1.027" spread="0.3528"/>
                    <measurement group_id="O4" value="1.077" spread="0.3256"/>
                    <measurement group_id="O5" value="0.992" spread="0.2981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4, Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.201" spread="0.1084"/>
                    <measurement group_id="O2" value="0.185" spread="0.1088"/>
                    <measurement group_id="O3" value="0.177" spread="0.0861"/>
                    <measurement group_id="O4" value="0.202" spread="0.0984"/>
                    <measurement group_id="O5" value="0.183" spread="0.0824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4, Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.206" spread="0.1037"/>
                    <measurement group_id="O2" value="0.195" spread="0.1079"/>
                    <measurement group_id="O3" value="0.190" spread="0.0875"/>
                    <measurement group_id="O4" value="0.215" spread="0.0965"/>
                    <measurement group_id="O5" value="0.179" spread="0.0824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4, Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.212" spread="0.1161"/>
                    <measurement group_id="O2" value="0.185" spread="0.1014"/>
                    <measurement group_id="O3" value="0.187" spread="0.0941"/>
                    <measurement group_id="O4" value="0.207" spread="0.0927"/>
                    <measurement group_id="O5" value="0.184" spread="0.0896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Biomarkers: Anti-Nuclear Antibodies (ANA)</title>
        <description>Serum biomarkers C3, C4, anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-nuclear antibody (ANA) and other autoantibodies were measured from blood serum samples collected on Day 85 and Day 169. No anti-dsDNA data was available for this report</description>
        <time_frame>At Day 85 and Day 169</time_frame>
        <population>All Treated participants with at Least One Post-Treatment Biomarker Measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Biomarkers: Anti-Nuclear Antibodies (ANA)</title>
          <description>Serum biomarkers C3, C4, anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-nuclear antibody (ANA) and other autoantibodies were measured from blood serum samples collected on Day 85 and Day 169. No anti-dsDNA data was available for this report</description>
          <population>All Treated participants with at Least One Post-Treatment Biomarker Measurement</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Negative Day 85 Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Negative Day 85 Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Positive Day 85 Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="1.8"/>
                    <measurement group_id="O4" value="2.0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Positive Day 85 Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7"/>
                    <measurement group_id="O2" value="96.6"/>
                    <measurement group_id="O3" value="98.2"/>
                    <measurement group_id="O4" value="98.0"/>
                    <measurement group_id="O5" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Negative Day 169 Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="57.1"/>
                    <measurement group_id="O5" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Negative Day 169 Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="42.9"/>
                    <measurement group_id="O5" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Positive Day 169 Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="5.8"/>
                    <measurement group_id="O4" value="4.3"/>
                    <measurement group_id="O5" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Positive Day 169 Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7"/>
                    <measurement group_id="O2" value="98.0"/>
                    <measurement group_id="O3" value="94.2"/>
                    <measurement group_id="O4" value="95.7"/>
                    <measurement group_id="O5" value="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Term: Receptor Occupancy Over Time</title>
        <description>Percent CD4+ Receptor Occupancy and percent CD8+ Receptor Occupancy</description>
        <time_frame>At Day 85 and Day 169</time_frame>
        <population>All Treated participants with at Least One Post-Treatment Biomarker Measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Short Term: Receptor Occupancy Over Time</title>
          <description>Percent CD4+ Receptor Occupancy and percent CD8+ Receptor Occupancy</description>
          <population>All Treated participants with at Least One Post-Treatment Biomarker Measurement</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>%CD4+ RO Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%CD4+ RO Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.722" spread="12.1298"/>
                    <measurement group_id="O2" value="83.244" spread="28.9616"/>
                    <measurement group_id="O3" value="70.520" spread="32.9107"/>
                    <measurement group_id="O4" value="37.155" spread="31.2927"/>
                    <measurement group_id="O5" value="0.350" spread="0.5997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%CD4+ RO Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.390" spread="22.1377"/>
                    <measurement group_id="O2" value="77.210" spread="29.3976"/>
                    <measurement group_id="O3" value="74.286" spread="28.5105"/>
                    <measurement group_id="O4" value="44.115" spread="34.3707"/>
                    <measurement group_id="O5" value="0.334" spread="0.4460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%CD8+ RO Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="57"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%CD8+ RO Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.831" spread="7.6571"/>
                    <measurement group_id="O2" value="81.730" spread="30.4345"/>
                    <measurement group_id="O3" value="68.960" spread="32.0543"/>
                    <measurement group_id="O4" value="32.516" spread="29.7242"/>
                    <measurement group_id="O5" value="0.160" spread="0.3120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%CD8+ RO Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.043" spread="20.6963"/>
                    <measurement group_id="O2" value="74.726" spread="33.0060"/>
                    <measurement group_id="O3" value="69.850" spread="30.5880"/>
                    <measurement group_id="O4" value="40.989" spread="31.9867"/>
                    <measurement group_id="O5" value="0.235" spread="0.5438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With BMS-931699 Induced Antibody Response Over Time Point Specified</title>
        <description>Immunogenicity defined as positive for anti-drug antibodies post-baseline measurement if baseline missing or negative. If baseline is positive, then immunogenicity is defined as a positive post-baseline measurement with titer value 4 times greater than baseline. (A) all subjects with a laboratory reported positive antibody responses to BMS-931699 during the short-term double-blind treatment period are included. Overall: At least one positive sample relative to baseline during short-term double-blind and follow-up period.</description>
        <time_frame>Day 169</time_frame>
        <population>All Treated participants with at Least One Post-Treatment Immunogenicity Assessment Who Developed Laboratory Reported Positive Antibody Responses to BMS-931699</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With BMS-931699 Induced Antibody Response Over Time Point Specified</title>
          <description>Immunogenicity defined as positive for anti-drug antibodies post-baseline measurement if baseline missing or negative. If baseline is positive, then immunogenicity is defined as a positive post-baseline measurement with titer value 4 times greater than baseline. (A) all subjects with a laboratory reported positive antibody responses to BMS-931699 during the short-term double-blind treatment period are included. Overall: At least one positive sample relative to baseline during short-term double-blind and follow-up period.</description>
          <population>All Treated participants with at Least One Post-Treatment Immunogenicity Assessment Who Developed Laboratory Reported Positive Antibody Responses to BMS-931699</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% with Neutralizing activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="41.2"/>
                    <measurement group_id="O3" value="64.7"/>
                    <measurement group_id="O4" value="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% with Neutralizing activity (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.9"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% with Neutralizing activity (Overall)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="35.3"/>
                    <measurement group_id="O3" value="64.7"/>
                    <measurement group_id="O4" value="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: HEMATOLOGY I</title>
        <description>HEMATOLOGY I: ERYTHROCYTE/PLATELET ATTRIBUTES HEMOGLOBIN G/L L &lt; 0.85×PRE-RX; HEMATOCRIT VOL L &lt; 0.85×PRE-RX; PLATELET COUNT X10*9 C/L H &gt; 1.5×ULN (ULN = Upper Limit of Normal) IF PRE-RX IS MISSING OR &gt; 1.5×ULN PLATELET COUNT X10*9 C/L L &lt; 0.85×LLN (LLN = Lower Limit of Normal) IF PRE-RX IS MISSING OR &lt; 0.85×LLN IF PRE-RX &gt;= LLN OR &lt; 0.85×PRE-RX IF PRE-RX &lt; LLN; ERYTHROCYTES RBC X10*12 C/L L &lt; 0.85×PRE-RX HEMATOLOGY II QUANTITATIVE WBC : LEUKOCYTES X10*9 C/L H &gt; 1.2×ULN IF PRE-RX IS MISSING OR &gt; 1.2×ULN IF LLN &lt;= PRE-RX &lt;= ULN OR &gt; 1.5×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; LEUKOCYTES WBC X10*9 C/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF LLN &lt;= PRE-RX &lt;= ULN OR &lt; 0.85×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN</description>
        <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: HEMATOLOGY I</title>
          <description>HEMATOLOGY I: ERYTHROCYTE/PLATELET ATTRIBUTES HEMOGLOBIN G/L L &lt; 0.85×PRE-RX; HEMATOCRIT VOL L &lt; 0.85×PRE-RX; PLATELET COUNT X10*9 C/L H &gt; 1.5×ULN (ULN = Upper Limit of Normal) IF PRE-RX IS MISSING OR &gt; 1.5×ULN PLATELET COUNT X10*9 C/L L &lt; 0.85×LLN (LLN = Lower Limit of Normal) IF PRE-RX IS MISSING OR &lt; 0.85×LLN IF PRE-RX &gt;= LLN OR &lt; 0.85×PRE-RX IF PRE-RX &lt; LLN; ERYTHROCYTES RBC X10*12 C/L L &lt; 0.85×PRE-RX HEMATOLOGY II QUANTITATIVE WBC : LEUKOCYTES X10*9 C/L H &gt; 1.2×ULN IF PRE-RX IS MISSING OR &gt; 1.2×ULN IF LLN &lt;= PRE-RX &lt;= ULN OR &gt; 1.5×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; LEUKOCYTES WBC X10*9 C/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF LLN &lt;= PRE-RX &lt;= ULN OR &lt; 0.85×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythrocytes Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count high</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quantitative WBC: Leukocytes low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quantitative WBC: Leukocytes high</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: HEMATOLOGY II</title>
        <description>WBC DIFFERENTIAL COUNT: BASOPHILS (ABSOLUTE) X10*9 C/L H &gt; 0.4; BLASTS (ABSOLUTE) X10*9 C/L H &gt; 0; EOSINOPHILS (ABSOLUTE) EOSA X10*9 C/L H &gt; 0.75; LYMPHOCYTES (ABSOLUTE) X10*9 C/L H &gt; 7.5; LYMPHOCYTES (ABSOLUTE) X10*9 C/L L &lt; 0.75; MONOCYTES (ABSOLUTE) X10*9 C/L H &gt; 2; NEUTROPHILS (ABSOLUTE) X10*9 C/L L &lt; 1.5 IF PRE-RX IS MISSING OR &lt; 1.5 IF PRE-RX &gt;= 1.5 OR &lt; 0.85×PRE-RX IF PRE-RX &lt; 1.5; COAGULATION activated Partial thromboplastin time (APTT) SEC H &gt; 1.5×ULN; INTL NORMALIZED RATIO (INR) INR FRACTION H &gt; 1.5×ULN PROTHROMBIN TIME (PT) PT SEC H &gt; 1.5×ULN</description>
        <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: HEMATOLOGY II</title>
          <description>WBC DIFFERENTIAL COUNT: BASOPHILS (ABSOLUTE) X10*9 C/L H &gt; 0.4; BLASTS (ABSOLUTE) X10*9 C/L H &gt; 0; EOSINOPHILS (ABSOLUTE) EOSA X10*9 C/L H &gt; 0.75; LYMPHOCYTES (ABSOLUTE) X10*9 C/L H &gt; 7.5; LYMPHOCYTES (ABSOLUTE) X10*9 C/L L &lt; 0.75; MONOCYTES (ABSOLUTE) X10*9 C/L H &gt; 2; NEUTROPHILS (ABSOLUTE) X10*9 C/L L &lt; 1.5 IF PRE-RX IS MISSING OR &lt; 1.5 IF PRE-RX &gt;= 1.5 OR &lt; 0.85×PRE-RX IF PRE-RX &lt; 1.5; COAGULATION activated Partial thromboplastin time (APTT) SEC H &gt; 1.5×ULN; INTL NORMALIZED RATIO (INR) INR FRACTION H &gt; 1.5×ULN PROTHROMBIN TIME (PT) PT SEC H &gt; 1.5×ULN</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils (Absolute) Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (Absolute) High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blasts (Absolute) Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blasts (Absolute) High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (Absolute) Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (Absolute) High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Absolute) Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Absolute) High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (Absolute) High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (Absolute) Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (Absolute) Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (Absolute) High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests : LIVER FUNCTION TESTS</title>
        <description>LIVER FUNCTION TESTS:ALKALINE PHOSPHATASE (ALP) ALP U/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN; ALANINE AMINOTRANSFERASE (ALT) ALT U/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN; ASPARTATE AMINOTRANSFERASE (AST) AST U/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN; BILIRUBIN, DIRECT UMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN G-GLUTAMYL TRANSFERASE (GGT) GGT U/L H &gt; 1.15×ULN IF PRE-RX IS MISSING OR &gt; 1.15×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN BILIRUBIN, TOTAL UMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN</description>
        <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests : LIVER FUNCTION TESTS</title>
          <description>LIVER FUNCTION TESTS:ALKALINE PHOSPHATASE (ALP) ALP U/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN; ALANINE AMINOTRANSFERASE (ALT) ALT U/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN; ASPARTATE AMINOTRANSFERASE (AST) AST U/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN; BILIRUBIN, DIRECT UMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN G-GLUTAMYL TRANSFERASE (GGT) GGT U/L H &gt; 1.15×ULN IF PRE-RX IS MISSING OR &gt; 1.15×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN BILIRUBIN, TOTAL UMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine Aminotransferase Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, Direct Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Direct, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Total, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Total, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: KIDNEY FUNCTION TESTS</title>
        <description>KIDNEY FUNCTION TESTS:BLOOD UREA NITROGEN MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN CREATININE UMOL/L H &gt; 1.5×ULN IF PRE-RX IS MISSING OR &gt; 1.5×ULN IF PRE-RX &lt;= ULN OR &gt; 1.33×PRE-RX IF PRE-RX &gt; ULN GLOMERULAR FILTRATION RATE, CALC. ML/S/M*2 L &lt; 0.8×PRE-RX; UREA UREA MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN</description>
        <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormalities in General Laboratory Tests: KIDNEY FUNCTION TESTS</title>
          <description>KIDNEY FUNCTION TESTS:BLOOD UREA NITROGEN MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN CREATININE UMOL/L H &gt; 1.5×ULN IF PRE-RX IS MISSING OR &gt; 1.5×ULN IF PRE-RX &lt;= ULN OR &gt; 1.33×PRE-RX IF PRE-RX &gt; ULN GLOMERULAR FILTRATION RATE, CALC. ML/S/M*2 L &lt; 0.8×PRE-RX; UREA UREA MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood Urea Nitrogen, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Urea Nitrogen, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLOMERULAR FILTRATION RATE, CALC. Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLOMERULAR FILTRATION RATE, CALC. High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests ELECTROLYTES 1</title>
        <description>CALCIUM, TOTAL MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; CALCIUM, TOTAL MMOL/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN; CHLORIDE, SERUM MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; CHLORIDE, SERUM MMOL/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN;</description>
        <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests ELECTROLYTES 1</title>
          <description>CALCIUM, TOTAL MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; CALCIUM, TOTAL MMOL/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN; CHLORIDE, SERUM MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; CHLORIDE, SERUM MMOL/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN;</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium, Total, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Total, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Serum, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Serum, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests: ELECTROLYTES 2</title>
        <description>BICARBONATE MMOL/L H &gt; 1.2×ULN IF PRE-RX IS MISSING OR &gt; 1.2×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; BICARBONATE MMOL/L L &lt; 0.8×LLN IF PRE-RX IS MISSING OR &lt; 0.8×LLN IF PRE-RX &gt;= LLN OR &lt; 0.8×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN; POTASSIUM, SERUM MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; POTASSIUM, SERUM MMOL/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN; MAGNESIUM, SERUM MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN MAGNESIUM, SERUM MMOL/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN</description>
        <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests: ELECTROLYTES 2</title>
          <description>BICARBONATE MMOL/L H &gt; 1.2×ULN IF PRE-RX IS MISSING OR &gt; 1.2×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; BICARBONATE MMOL/L L &lt; 0.8×LLN IF PRE-RX IS MISSING OR &lt; 0.8×LLN IF PRE-RX &gt;= LLN OR &lt; 0.8×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN; POTASSIUM, SERUM MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN; POTASSIUM, SERUM MMOL/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN; MAGNESIUM, SERUM MMOL/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN MAGNESIUM, SERUM MMOL/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bicarbonate, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium, Serum, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium, Serum, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Serum, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Serum, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests: ELECTROLYTES 3</title>
        <description>SODIUM, SERUM MMOL/L H &gt; 1.05×ULN IF PRE-RX IS MISSING OR &gt; 1.05×ULN IF PRE-RX &lt;= ULN OR &gt; 1.05×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN SODIUM, SERUM MMOL/L L &lt; 0.95×LLN IF PRE-RX IS MISSING OR &lt; 0.95×LLN IF PRE-RX &gt;= LLN OR &lt; 0.95×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN PHOSPHORUS, INORGANIC PHOS MMOL/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN PHOSPHORUS, INORGANIC PHOS MMOL/L L &lt; 0.85×LLN IF PRE-RX IS MISSING OR &lt; 0.85×LLN IF PRE-RX &gt;=LLN OR &lt; 0.85×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN</description>
        <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests: ELECTROLYTES 3</title>
          <description>SODIUM, SERUM MMOL/L H &gt; 1.05×ULN IF PRE-RX IS MISSING OR &gt; 1.05×ULN IF PRE-RX &lt;= ULN OR &gt; 1.05×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN SODIUM, SERUM MMOL/L L &lt; 0.95×LLN IF PRE-RX IS MISSING OR &lt; 0.95×LLN IF PRE-RX &gt;= LLN OR &lt; 0.95×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN PHOSPHORUS, INORGANIC PHOS MMOL/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN PHOSPHORUS, INORGANIC PHOS MMOL/L L &lt; 0.85×LLN IF PRE-RX IS MISSING OR &lt; 0.85×LLN IF PRE-RX &gt;=LLN OR &lt; 0.85×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium, Serum Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Serum High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, Inorganic, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, Inorganic, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 1</title>
        <description>GLUCOSE TESTS:GLUCOSE, FASTING SERUM MMOL/L H &gt; 1.3×ULN IF PRE-RX IS MISSING OR &gt; 1.3×ULN IF PRE-RX &lt;= ULN OR &gt; 2×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN GLUCOSE, FASTING SERUM MMOL/L L &lt; 0.8×LLN IF PRE-RX IS MISSING OR &lt; 0.8×LLN IF PRE-RX &gt;= LLN OR &lt; 0.8×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN; PROTEIN TESTS:ALBUMIN G/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN PROTEIN, TOTAL G/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN PROTEIN, TOTAL G/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN</description>
        <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 1</title>
          <description>GLUCOSE TESTS:GLUCOSE, FASTING SERUM MMOL/L H &gt; 1.3×ULN IF PRE-RX IS MISSING OR &gt; 1.3×ULN IF PRE-RX &lt;= ULN OR &gt; 2×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN GLUCOSE, FASTING SERUM MMOL/L L &lt; 0.8×LLN IF PRE-RX IS MISSING OR &lt; 0.8×LLN IF PRE-RX &gt;= LLN OR &lt; 0.8×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN; PROTEIN TESTS:ALBUMIN G/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN PROTEIN, TOTAL G/L H &gt; 1.1×ULN IF PRE-RX IS MISSING OR &gt; 1.1×ULN IF PRE-RX &lt;= ULN OR &gt; 1.1×PRE-RX IF PRE-RX &gt; ULN OR &gt; ULN IF PRE-RX &lt; LLN PROTEIN, TOTAL G/L L &lt; 0.9×LLN IF PRE-RX IS MISSING OR &lt; 0.9×LLN IF PRE-RX &gt;= LLN OR &lt; 0.9×PRE-RX IF PRE-RX &lt; LLN OR &lt; LLN IF PRE-RX &gt; ULN</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, Fasting serum, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Fasting Serum, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Total, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Total, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 2</title>
        <description>OTHER CHEMISTRY TESTING LIPID TESTS: CHOLESTEROL, TOTAL (TC) MMOL/L H &gt; 1.2×ULN IF PRE-RX IS MISSING OR &gt; 1.2×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN TRIGLYCERIDES, FASTING MMOL/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.5×PRE-RX IF PRE-RX &gt; ULN PANCREATIC TESTS: AMYLASE, TOTAL U/L H &gt; 1.5×ULN; LIPASE, TOTAL (TURBIDIMETRIC ASSAY) U/L H &gt; 1.5×ULN; LIPASE, TOTAL (COLORIMETRIC ASSAY) U/L H &gt; 1.5×ULN; ENDOCRINE TESTS:CORTISOL, AM NMOL/L L &lt; 138 THYROID STIMULATING HORMONE (TSH) TSH MU/L H &gt; 1.5×ULN IF PRE-RX IS MISSING OR &gt; 1.5×ULN IF PRE-RX &lt;= ULN OR &gt; 2×PRE-RX IF PRE-RX &gt; ULN</description>
        <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 2</title>
          <description>OTHER CHEMISTRY TESTING LIPID TESTS: CHOLESTEROL, TOTAL (TC) MMOL/L H &gt; 1.2×ULN IF PRE-RX IS MISSING OR &gt; 1.2×ULN IF PRE-RX &lt;= ULN OR &gt; 1.2×PRE-RX IF PRE-RX &gt; ULN TRIGLYCERIDES, FASTING MMOL/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.5×PRE-RX IF PRE-RX &gt; ULN PANCREATIC TESTS: AMYLASE, TOTAL U/L H &gt; 1.5×ULN; LIPASE, TOTAL (TURBIDIMETRIC ASSAY) U/L H &gt; 1.5×ULN; LIPASE, TOTAL (COLORIMETRIC ASSAY) U/L H &gt; 1.5×ULN; ENDOCRINE TESTS:CORTISOL, AM NMOL/L L &lt; 138 THYROID STIMULATING HORMONE (TSH) TSH MU/L H &gt; 1.5×ULN IF PRE-RX IS MISSING OR &gt; 1.5×ULN IF PRE-RX &lt;= ULN OR &gt; 2×PRE-RX IF PRE-RX &gt; ULN</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol, Total (TC) Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol, Total (TC) High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, Fasting Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, Fasting High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase, Total Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase, Total High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, Total (Colorimetric Assay) Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, Total (Colorimetric Assay) High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, Total (Turbidimetric Assay) Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, Total (Turbidimetric Assay) High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid Stimulating Hormone, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid Stimulating Hormone, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 3</title>
        <description>OTHER CHEMISTRY TESTING CARDIAC TESTS: CREATINE KINASE (CK) CK U/L H &gt; 1.5×ULN IF PRE-RX IS MISSING OR &gt; 1.5×ULN IF PRE-RX &lt;= ULN OR &gt; 1.5×PRE-RX IF PRE-RX &gt; ULN; TROPONIN-I, CARDIAC SPECIFIC UG/L H &gt; ULN; METABOLITE TESTS:URIC ACID URIC MMOL/L H &gt; 1.2×ULN IF PRE-RX IS MISSING OR &gt; 1.2×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN; CHEM TEST, MULTI INDICATIONS : LACTATE DEHYDROGENASE (LD) LD U/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.5×PRE-RX IF PRE-RX &gt; ULN</description>
        <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : OTHER CHEMISTRY TESTING 3</title>
          <description>OTHER CHEMISTRY TESTING CARDIAC TESTS: CREATINE KINASE (CK) CK U/L H &gt; 1.5×ULN IF PRE-RX IS MISSING OR &gt; 1.5×ULN IF PRE-RX &lt;= ULN OR &gt; 1.5×PRE-RX IF PRE-RX &gt; ULN; TROPONIN-I, CARDIAC SPECIFIC UG/L H &gt; ULN; METABOLITE TESTS:URIC ACID URIC MMOL/L H &gt; 1.2×ULN IF PRE-RX IS MISSING OR &gt; 1.2×ULN IF PRE-RX &lt;= ULN OR &gt; 1.25×PRE-RX IF PRE-RX &gt; ULN; CHEM TEST, MULTI INDICATIONS : LACTATE DEHYDROGENASE (LD) LD U/L H &gt; 1.25×ULN IF PRE-RX IS MISSING OR &gt; 1.25×ULN IF PRE-RX &lt;= ULN OR &gt; 1.5×PRE-RX IF PRE-RX &gt; ULN</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatine Kinase Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TROPONIN-I, CARDIAC SPECIFIC Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TROPONIN-I, CARDIAC SPECIFIC High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase (LD) low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase (LD) high</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : IMMUNOLOGY</title>
        <description>IMMUNE ACTIVATION MARKERS:C-REACTIVE PROTEIN (CRP) CRP MG/L H &gt; 1.5×ULN; CRP, HIGH SENSITIVITY MG/L H &gt; 1.5×ULN;</description>
        <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : IMMUNOLOGY</title>
          <description>IMMUNE ACTIVATION MARKERS:C-REACTIVE PROTEIN (CRP) CRP MG/L H &gt; 1.5×ULN; CRP, HIGH SENSITIVITY MG/L H &gt; 1.5×ULN;</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-Reactive Protein (CRP) Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="64"/>
                    <count group_id="O5" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-Reactive Protein (CRP) High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="64"/>
                    <count group_id="O5" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP, High Sensitivity Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP, High Senstivity High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : URINALYSIS</title>
        <description>QUALITATIVE URINE CHEMISTRY: BLOOD, URINE N/A H &gt;= 2 IF PRE-RX IS MISSING OR &gt;= 2 IF PRE-RX &lt; 1 OR &gt;= 2×PRE-RX IF PRE-RX &gt;= 1 GLUCOSE, URINE N/A H &gt;= 1 IF PRE-RX IS MISSING OR &gt;= 1 IF PRE-RX &lt; 1 OR &gt;= 2×PRE-RX IF PRE-RX &gt;= 1 PROTEIN, URINE UNKNOWN H &gt;= 2 IF PRE-RX IS MISSING OR &gt;= 2 IF PRE-RX &lt; 1 OR &gt;= 2×PRE-RX IF PRE-RX &gt;= 1 URINALYSIS II URINE WBC + RBC ; RBC, URINE HPF H &gt;= 2 IF PRE-RX IS MISSING OR &gt;= 2 IF PRE-RX &lt; 2 OR &gt;= 4 IF PRE-RX &gt;= 2 WBC, URINE HPF H &gt;= 2 IF PRE-RX IS MISSING OR &gt;= 2 IF PRE-RX &lt; 2 OR &gt;= 4 IF PRE-RX &gt;= 2</description>
        <time_frame>Up to 42 days post last dose of study medication in short-term or long-term extension period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Clinically Significant Abnormalities in General Laboratory Tests : URINALYSIS</title>
          <description>QUALITATIVE URINE CHEMISTRY: BLOOD, URINE N/A H &gt;= 2 IF PRE-RX IS MISSING OR &gt;= 2 IF PRE-RX &lt; 1 OR &gt;= 2×PRE-RX IF PRE-RX &gt;= 1 GLUCOSE, URINE N/A H &gt;= 1 IF PRE-RX IS MISSING OR &gt;= 1 IF PRE-RX &lt; 1 OR &gt;= 2×PRE-RX IF PRE-RX &gt;= 1 PROTEIN, URINE UNKNOWN H &gt;= 2 IF PRE-RX IS MISSING OR &gt;= 2 IF PRE-RX &lt; 1 OR &gt;= 2×PRE-RX IF PRE-RX &gt;= 1 URINALYSIS II URINE WBC + RBC ; RBC, URINE HPF H &gt;= 2 IF PRE-RX IS MISSING OR &gt;= 2 IF PRE-RX &lt; 2 OR &gt;= 4 IF PRE-RX &gt;= 2 WBC, URINE HPF H &gt;= 2 IF PRE-RX IS MISSING OR &gt;= 2 IF PRE-RX &lt; 2 OR &gt;= 4 IF PRE-RX &gt;= 2</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood, Urine, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood, Urine, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Urine, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Urine, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Urine, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Urine, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="68"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Urine, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Urine, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Urine, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                    <measurement group_id="O3" value="NA">Not evaluated</measurement>
                    <measurement group_id="O4" value="NA">Not evaluated</measurement>
                    <measurement group_id="O5" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Urine, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the SLEDAI-2K Score of SLE Activity on Day 85 and Day 169</title>
        <description>Systemic Lupus Erythematosus Disease Activity Index, SLEDAI; Version 2000, also known as SLEDAI-2K. The SLEDAI-2K score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
        <time_frame>At baseline, Day 85 and Day 169</time_frame>
        <population>All randomized and treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the SLEDAI-2K Score of SLE Activity on Day 85 and Day 169</title>
          <description>Systemic Lupus Erythematosus Disease Activity Index, SLEDAI; Version 2000, also known as SLEDAI-2K. The SLEDAI-2K score is a weighted, cumulative index of lupus disease activity. SLEDAI-2K is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105.</description>
          <population>All randomized and treated participants</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SLEDAI-2K Score Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.61" spread="3.345"/>
                    <measurement group_id="O2" value="-3.24" spread="3.320"/>
                    <measurement group_id="O3" value="-3.17" spread="3.304"/>
                    <measurement group_id="O4" value="-4.02" spread="3.960"/>
                    <measurement group_id="O5" value="-3.29" spread="3.953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLEDAI-2K Score Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.88" spread="3.370"/>
                    <measurement group_id="O2" value="-4.17" spread="4.064"/>
                    <measurement group_id="O3" value="-3.98" spread="3.478"/>
                    <measurement group_id="O4" value="-4.82" spread="4.078"/>
                    <measurement group_id="O5" value="-4.15" spread="3.728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician Global Assessment of Disease Activity (MDGA) on Day 85 and Day 169</title>
        <description>Physician Global Assessment of Arthritis was measured by asking the physician to assess the participant's current arthritis disease activity by placing a vertical line on a 0 to 100 millimeter (mm) visual analog scale (VAS), where 0 mm = very good and 100 mm = very bad.</description>
        <time_frame>At baseline, Day 85 and Day 169</time_frame>
        <population>All randomized and treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: 12.5mg SC BMS-931699 Weekly</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: 12.5mg SC BMS-931699 Every Other Week</title>
            <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O3">
            <title>Experimental: 5mg SC Injection BMS-931699 Every Other Week</title>
            <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
          </group>
          <group group_id="O4">
            <title>Experimental: 1.25mg SCBMS-931699 Every Other Week</title>
            <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW</description>
          </group>
          <group group_id="O5">
            <title>Placebo Comparator: 0mg SC Weekly BMS-931699</title>
            <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Assessment of Disease Activity (MDGA) on Day 85 and Day 169</title>
          <description>Physician Global Assessment of Arthritis was measured by asking the physician to assess the participant's current arthritis disease activity by placing a vertical line on a 0 to 100 millimeter (mm) visual analog scale (VAS), where 0 mm = very good and 100 mm = very bad.</description>
          <population>All randomized and treated participants</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MDGA score Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.77" spread="18.193"/>
                    <measurement group_id="O2" value="-23.87" spread="20.321"/>
                    <measurement group_id="O3" value="-21.00" spread="20.596"/>
                    <measurement group_id="O4" value="-20.55" spread="17.233"/>
                    <measurement group_id="O5" value="-23.83" spread="20.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDGA score Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.30" spread="17.371"/>
                    <measurement group_id="O2" value="-26.87" spread="21.284"/>
                    <measurement group_id="O3" value="-28.68" spread="19.919"/>
                    <measurement group_id="O4" value="-26.71" spread="18.182"/>
                    <measurement group_id="O5" value="-25.28" spread="19.952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All non-serious adverse events (NSAEs) and serious adverse events (SAEs) are reported from onset on or after the first dose date of study medication and up to 42 days post last dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Short Term (ST)</title>
          <description>Subjects received 0 milligram (mg) subcutaneous (SC) injection of matching placebo weekly.</description>
        </group>
        <group group_id="E2">
          <title>Lulizumab Pegol 12.5 mg Weekly - ST</title>
          <description>Subjects received 12.5 mg SC injection of lulizumab pegol weekly.</description>
        </group>
        <group group_id="E3">
          <title>Lulizumab Pegol 12.5 mg EOW - ST</title>
          <description>Subjects received 12.5 mg SC injection of lulizumab pegol EOW.</description>
        </group>
        <group group_id="E4">
          <title>Lulizumab Pegol 5 mg EOW - ST</title>
          <description>Subjects received 5 mg SC injection of lulizumab pegol EOW.</description>
        </group>
        <group group_id="E5">
          <title>Lulizumab Pegol 1.25 mg Every Other Week (EOW) - ST</title>
          <description>Subjects received 1.25 mg lulizumab pegol SC injection EOW.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lupus enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Zika virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Putamen haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Imminent abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please email</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

